Abstract:Background: As deregulation of androgen receptor (AR) signaling target genes is associated with tumorigenesis and the development of prostate cancer (PCa), AR signaling is the primary therapeutic target for PCa. Although patients initially responses to first-line androgen deprivation therapies (ADTs), most of them with advanced PCa progress to lethal castration-resistant prostate cancer (CRPC). Recent studies have suggested the molecular mechanisms by which AR elicit the robust up-regulation of the FKBP51 gene. We suggest that restored expression of FKBP51 gene, modulated by androgen receptor splicing variant 7 (AR-V7) which replaces full length androgen receptor (AR-FL) in androgen ablation status, promotes CRPC progression through activating NF-kappa B signaling. Methods: Immunohistochemistry assays were used to detect the expression of AR-V7, FKBP51 and NF-kappa B signaling correlated proteins in CRPC tissues. An androgen ablation resistant PCa cell line model established by Long-term culturing in androgen depleted medium, named androgen-independent LNCaP (LNCaP-AI) cells, were used to dynamically monitor FKBP51 expression during the process of androgen dependent PCa cells transforming into androgen-independent cells, as well as its association with NF-kappa B signal pathway. LNCaP-AI cell line was determined to express AR-V7 protein continuously. Luciferase reporter assays and DNA pull down were used to determine the association between AR-V7 and FKBP51. Results: Our results suggested that CRPC patients with AR-V7 high expression tend to have higher expression of FKBP51 and enhanced NF-kappa B signaling compared with AR-V7 negative patients. Knockdown of AR-V7 or FKBP51 in LNCaP-AI cells attenuated the level of p-NF-kappa B (Ser536) and androgen-resistant cells growth. Luciferase reporter assays and DNA pull down results indicated that FKBP51 was transcriptionally promoted by AR-V7 in absence of androgen, which enhanced NF-kappa B signaling. Conclusions: Because of upregulation of AR-V7 in androgen-independent PCa cells, increasing of FKBP51 induced NF-kappa B signaling, leading to progression of CRPC.

CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression

SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain

Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells.

Orphan Nuclear Receptor TLX Contributes to Androgen Insensitivity in Castration-Resistant Prostate Cancer Via Its Repression of Androgen Receptor Transcription.

Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Casein kinase 2 inhibitor reduces androgen receptor function and cell proliferation in prostate cancer cells

Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells

Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer

CAMK2N1 Inhibits Prostate Cancer Progression Through Androgen Receptor-Dependent Signaling

Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer

Restoration of FKBP51 Protein Promotes the Progression of Castration Resistant Prostate Cancer

Data from Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer

CYP19A1 is Downregulated by BRD4 and Suppresses Castration-Resistant Prostate Cancer Cell Invasion and Proliferation by Decreasing AR Expression.

Mesoporous Silica Nanoparticles Combined with AKR1C3 Sirna Inhibited the Growth of Castration-Resistant Prostate Cancer by Suppressing Androgen Synthesis in Vitro and in Vivo

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

Combination of the NRF2 Inhibitor and Autophagy Inhibitor Significantly Inhibited Tumorigenicity of Castration-Resistant Prostate Cancer

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling

Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer

A Novel AR Translational Regulator Lncrna LBCS Inhibits Castration Resistance of Prostate Cancer.